Phaseline

Companies › Shanghai Institute Of Biological Products

Shanghai Institute Of Biological Products: clinical trials, targets and expected readouts

10 active drug programs in 11 registered trials: 10 Phase 1, 1 Phase 2; Oncology, Infectious disease, Metabolic and endocrine; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
SIBP-03
HER3 monoclonal antibody
ERBB3Phase 2Head and Neck Squamous Cell Carcinoma–
SIBP-A17
HER2-targeted antibody-drug conjugate (ADC)
ERBB2Phase 1Advanced Solid TumorDec 2026
SIBP-R002 (Peguricase for injection)
Non-selective xanthine oxidase inhibitor
XDHPhase 1GoutDec 2026
Recombinant herpes zoster vaccine with low-dose adjuvant (Candidate 1)
Recombinant herpes zoster vaccine with low-dose adjuvant
–Phase 1Herpes Zoster (HZ)Dec 2027
SIBP-A18
anti-CLDN18.2 antibody-drug conjugate
CLDN18Phase 1Solid Tumor MalignancyMay 2028
SIBP-A19–Phase 1Advanced Solid TumorsDec 2028
SIBP-A10–Phase 1Advanced TumorsDec 2028
Influenza virus split vaccine (0.7mL/vial)
Inactivated split influenza vaccine containing hemagglutinin antigens from H1N1, H3N2, and
–Phase 1Influenza–
MVA strain monkeypox attenuated live vaccine
Attenuated live monkeypox vaccine (MVA strain)
–Phase 1Monkeypox–
SIBP-A13
HER3-targeting antibody-drug conjugate
ERBB3Phase 1Advanced Solid Tumor–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06771479MVA strain monkeypox attenuated live vaccinePhase 1MonkeypoxInfectious diseaseJan 2026
NCT06298058SIBP-A13Phase 1Advanced Solid TumorOncologyApr 2026
NCT06194656SIBP-03Phase 2Head and Neck Squamous Cell CarcinomaOncologyJul 2026
NCT07302256Influenza virus split vaccine (0.7mL/vial)Phase 1InfluenzaInfectious diseaseAug 2026
NCT06512116SIBP-A17Phase 1Advanced Solid TumorOncologyDec 2026
NCT06298071SIBP-R002 (Peguricase for injection)Phase 1GoutMetabolic and endocrineDec 2026
NCT06932523Recombinant herpes zoster vaccine with low-dose adjuvant (Candidate 1)Phase 1Herpes Zoster (HZ)Infectious diseaseDec 2027
NCT06932523Recombinant herpes zoster vaccine with low-dose adjuvant (Candidate 1)Phase 1Herpes Zoster (HZ)Infectious diseaseDec 2027
NCT06985368SIBP-A18Phase 1Solid Tumor MalignancyOncologyMay 2028
NCT06990464SIBP-A19Phase 1Advanced Solid TumorsOncologyDec 2028
NCT07205198SIBP-A10Phase 1Advanced TumorsOncologyDec 2028

Targets

ERBB3 (2) CLDN18 (1) ERBB2 (1) XDH (1)

Companies with the same targets

Beijing Biotech Roche Shenyang Sunshine Pharmaceutical AstraZeneca Astellas Jiangsu HengRui Medicine Daiichi Sankyo Hummingbird Bioscience Merck & Co. (MSD) Partner Therapeutics

Companies built like this

DualityBio Shenyang Sunshine Pharmaceutical SystImmune BioRay Pharmaceutical Alentis Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.